43 results on '"Ibrahim, Nasrien E."'
Search Results
2. Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy
3. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee
4. Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
5. Temporal Changes in Racial and Ethnic Disparities in the Utilization of Left Atrial Appendage Occlusion in the United States
6. Heart Failure Epidemiology and Outcomes Statistics: A Report of the Heart Failure Society of America
7. Organ Donation and Transplantation among Non-US Citizens: Opportunities to Improve Global Equity in Heart Transplantation
8. Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy
9. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates
10. The Impact of Health Care Disparities on Patients With Heart Failure
11. Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study
12. Racial, Ethnic, and Sex Disparities in Patients With STEMI and Cardiogenic Shock
13. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee
14. Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
15. Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
16. Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction
17. Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea
18. Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC: Heart Failure Position Paper
19. Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death
20. Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays
21. The Wallet Biopsy: Medical Crowdfunding for Heart Transplantation
22. 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
23. Readability and Accessibility of Patient-Education Materials for Heart Failure in the United States
24. Serial Heart Rates, Guideline-Directed Beta Blocker Use, and Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction
25. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study)
26. The Quagmire of Prognostication in Heart Failure: The Case for Equity Through Modeled Predictions
27. NT-proBNP Concentrations in the Community: Elevation, Deficiency, and Everything in Between
28. As We Embark on a Second Year
29. IS IT TIME TO UPDATE THE CLASSIFICATION OF HEART FAILURE AS HEART FAILURE WITH OR WITHOUT EVIDENCE OF SYSTOLIC DYSFUNCTION?
30. A Look Back, A Path Forward: Moving Toward Diversity and Inclusion in Cardiovascular Society Presidents
31. Personalizing Comprehensive Disease-Modifying Therapy: Obstacles and Opportunities
32. From Clinical Trials to Communities: The 5 C’s of Ensuring Equitable Delivery of Heart Failure Therapies
33. Don’t Be So Fast to Discard That Clean Catch!
34. How Feeling Like an Imposter Can Impede Your Success
35. Promoting Health Equity in Heart Failure Amid a Pandemic
36. Understanding the Mechanistic Benefit of Heart Failure Drugs Matters
37. Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/valsartan
38. Atrial Natriuretic Peptide Mediates Reverse Cardiac Remodeling During Treatment with Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction
39. Sex-based Differences in Biomarkers, Quality of Life, and Reverse Cardiac Remodeling in Patients with Heart Failure with Reduced Ejection Fraction Treated with Sacubitril/valsartan
40. First Experience with Feasibility and Implementation of the Smartphone Habits Heart® App: A Proof-of-Concept Study for Patient Engagement in Heart Failure Management
41. Are Guidelines Merely Suggestions?
42. ENDOTHELIN-1 PREDICTS INCIDENT HEART FAILURE, INCIDENT MYOCARDIAL INFARCTION, CARDIOVASCULAR MORTALITY, AND ALL-CAUSE MORTALITY IN PATIENTS UNDERGOING DIAGNOSTIC CORONARY ANGIOGRAPHY: RESULTS FROM THE CATHETER SAMPLED BLOOD ARCHIVE IN CARDIOVASCULAR DISEASES (CASABLANCA) STUDY
43. WORSENING RENAL FUNCTION DURING AGGRESSIVE HEART FAILURE MANAGEMENT IS NOT ASSOCIATED WITH POOR OUTCOMES: RESULTS FROM THE PRO-BNP OUTPATIENT TAILORED CHRONIC HEART FAILURE THERAPY (PROTECT) STUDY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.